G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019
July 31, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 31, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer
July 30, 2019 07:01 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of Mark Avagliano as Chief...
G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer
June 18, 2019 06:00 ET
|
G1 Therapeutics
- Detailed data from this trial will be presented at a medical meeting later this year - RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a...
G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019 Annual Meeting
June 14, 2019 07:01 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 14, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that an analysis of patient-reported outcomes...
G1 Therapeutics Announces Updates to Board of Directors
June 13, 2019 07:01 ET
|
G1 Therapeutics
- Garry Nicholson to serve as new board chair -- Sir Andrew Witty, Fredric Eshelman, Pharm.D. and prior chair Seth Rudnick, M.D. re-elected - RESEARCH TRIANGLE PARK, N.C., June 13, 2019 (GLOBE...
G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference
June 11, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2019 16:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 01, 2019 (GLOBE NEWSWIRE) -- - New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients - G1 Therapeutics, Inc. (Nasdaq:...
G1 Therapeutics to Present Additional Trilaciclib Phase 2 Small Cell Lung Cancer Data at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 16, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that additional findings from a Phase 2...
G1 Therapeutics to Present at UBS Global Healthcare Conference
May 13, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 13, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update
May 09, 2019 16:01 ET
|
G1 Therapeutics
Plans to submit U.S. and European marketing applications for trilaciclib following regulatory feedback First clinical data on oral SERD G1T48 expected in 3Q19Management to host webcast and conference...